drugset / Trial / NCT04986852
Olinvacimab With Pembrolizumab in Patients With mTNBC
NaSingle-groupOpen-labelTreatment
Summary
The objective is to evaluate the efficacy and safety of Olinvacimab in combination with Pembrolizumab in patients with mTNBC.
Timeline
- Start
- 2021-09-30
- Primary completion
- 2024-12-03
- Completion
- 2024-12-03
Outcome
Outcome not reported
Stopped (Enrollment): “Subject recruitment issues and follow-up study plans”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olinvacimab | Monoclonal antibody | 16 mg/kg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |